GoodRx (NASDAQ:GDRX) Upgraded at KeyCorp

KeyCorp upgraded shares of GoodRx (NASDAQ:GDRX) from a sector weight rating to an overweight rating in a research report report published on Wednesday morning, MarketBeat reports. KeyCorp currently has $9.00 price target on the stock.

A number of other equities analysts have also commented on the company. SVB Leerink began coverage on GoodRx in a research note on Monday, February 26th. They issued an outperform rating and a $8.00 price objective on the stock. Wells Fargo & Company raised GoodRx from an equal weight rating to an overweight rating and lifted their target price for the stock from $7.50 to $10.00 in a research report on Monday, March 25th. The Goldman Sachs Group lifted their target price on GoodRx from $6.50 to $7.50 and gave the stock a neutral rating in a research report on Friday, March 1st. TD Cowen lifted their target price on GoodRx from $12.00 to $14.00 and gave the stock an outperform rating in a research report on Friday, March 1st. Finally, Bank of America downgraded GoodRx from a buy rating to an underperform rating and decreased their target price for the stock from $8.00 to $4.50 in a research report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, GoodRx presently has a consensus rating of Hold and an average price target of $8.78.

GoodRx Price Performance

NASDAQ GDRX opened at $6.83 on Wednesday. GoodRx has a fifty-two week low of $4.14 and a fifty-two week high of $9.37. The stock’s 50-day moving average is $6.86 and its two-hundred day moving average is $6.17. The company has a debt-to-equity ratio of 0.85, a quick ratio of 7.12 and a current ratio of 7.12.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Thursday, February 29th. The company reported $0.02 earnings per share for the quarter, meeting the consensus estimate of $0.02. The company had revenue of $196.64 million for the quarter, compared to analyst estimates of $195.59 million. GoodRx had a positive return on equity of 2.45% and a negative net margin of 1.18%. Equities research analysts anticipate that GoodRx will post 0.23 EPS for the current year.

Institutional Trading of GoodRx

Several institutional investors and hedge funds have recently made changes to their positions in the business. Moneta Group Investment Advisors LLC raised its position in shares of GoodRx by 112,694.0% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 17,148,069 shares of the company’s stock valued at $79,910,000 after acquiring an additional 17,132,866 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of GoodRx by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 8,681,111 shares of the company’s stock valued at $48,875,000 after buying an additional 177,961 shares during the period. Rubric Capital Management LP acquired a new position in shares of GoodRx in the 4th quarter valued at $39,348,000. Millennium Management LLC grew its holdings in shares of GoodRx by 151.3% in the 4th quarter. Millennium Management LLC now owns 5,318,603 shares of the company’s stock valued at $24,785,000 after buying an additional 3,202,061 shares during the period. Finally, Ameriprise Financial Inc. grew its holdings in shares of GoodRx by 459.0% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,631,227 shares of the company’s stock valued at $14,814,000 after buying an additional 2,160,541 shares during the period. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.